Skip to main content


Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice

Fig. 4

Coronary flow was studied over time in lean, ob/ob−/− treated and untreated mice using non-invasive transthoracic ultrasound. Coronary flow velocity reserve (CFVR) a was calculated as the ratio of b coronary hyperemic and c basal flow velocities. Statistical significance between groups was tested using Anova, and where there were differences Turkey’s multiple comparison test was carried out. Values are presented as mean with standard deviation, where *p < 0.05 and **p < 0.01 for significant difference between lean controls and ob/ob−/− groups. p ≤ 0.05 for ob/ob−/− treated and untreated group

Back to article page